Balsm Alofoq Medical Company (TADAWUL:9620)

TADAWUL:9620 Balance Sheet

Financials in millions SAR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	5.33	3.68	5.74
Cash & Short-Term Investments	5.33	3.68	5.74
Cash Growth	-	-35.90%	-
Accounts Receivable	0.33	0.3	0.3
Other Receivables	0.17	0.04	0.02
Receivables	0.5	0.34	0.32
Inventory	1.22	1.5	0.68
Other Current Assets	0.63	0.28	0.66
Total Current Assets	7.69	5.8	7.39
Property, Plant & Equipment	12.54	12.86	7.51
Total Assets	20.23	18.66	14.9
Accounts Payable	0.31	0.34	0.44
Accrued Expenses	0.84	0.84	0.62
Current Portion of Leases	0.27	0.23	0.5
Current Income Taxes Payable	0.05	0.1	0.12
Other Current Liabilities	0.04	0.01	2.69
Total Current Liabilities	1.56	1.52	4.37
Long-Term Leases	1.7	1.69	2.13
Total Liabilities	4.41	4.27	7.54
Common Stock	10	10	4.9
Retained Earnings	5.82	3.96	2.11
Comprehensive Income & Other	-	0.43	0.35
Shareholders' Equity	15.82	14.39	7.36
Total Liabilities & Equity	20.23	18.66	14.9
Total Debt	2.01	1.93	2.62
Net Cash (Debt)	3.32	1.75	3.11
Net Cash Growth	-	-43.71%	-
Working Capital	6.13	4.28	3.02
Tangible Book Value	15.82	14.39	7.36
Land	5.13	5.13	-
Buildings	1.67	1.67	-
Machinery	6.32	6.27	6.17
Leasehold Improvements	2.82	2.8	2.55

Source: S&P Global Market Intelligence. Standard template. Financial Sources.